Syndax Pharmaceuticals (SNDX) News Today $13.66 +0.03 (+0.22%) (As of 09:39 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period State Street Corp Has $72.59 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)State Street Corp boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 4.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,770,826 shares of the company's stockDecember 18 at 3:35 AM | marketbeat.comShort Interest in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Rises By 35.8%Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 14,400,000 shares, an increase of 35.8% from the November 15th total of 10,600,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the short-interest ratio is currently 9.7 days.December 15 at 1:11 PM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down - Should You Sell?Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down - Should You Sell?December 13, 2024 | marketbeat.comY Intercept Hong Kong Ltd Boosts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Y Intercept Hong Kong Ltd boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 319.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,302 shares of tDecember 11, 2024 | marketbeat.comSyndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday.December 10, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Holdings Trimmed by Wellington Management Group LLPWellington Management Group LLP lessened its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 32.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,985,976 shares of theDecember 10, 2024 | marketbeat.comTwo Sigma Advisers LP Grows Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Two Sigma Advisers LP grew its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 7.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 669,352 shares of the company's stock after acquiring an additional 48,100 shares durDecember 10, 2024 | marketbeat.comPositive Outlook for Syndax Pharmaceuticals Amid Efficacy and Safety ConsiderationsDecember 9, 2024 | markets.businessinsider.comSyndax announces additional positive data from AUGMENT-101 trial of RevuforjDecember 9, 2024 | markets.businessinsider.comSyndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination TrialDecember 9, 2024 | prnewswire.comCharles Schwab Investment Management Inc. Acquires 41,458 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Charles Schwab Investment Management Inc. increased its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 6.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 695,947 shaDecember 9, 2024 | marketbeat.comSyndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual MeetingDecember 7, 2024 | prnewswire.comVerition Fund Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Verition Fund Management LLC trimmed its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 45.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 79,341 shares of the company's stock after selDecember 7, 2024 | marketbeat.comBuy Recommendation on Syndax Pharmaceuticals: Revumenib’s Market Potential and Upcoming CatalystsDecember 6, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Sells 67,086 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Point72 Asset Management L.P. lowered its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 2.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,778,267 shares of the company's stock after selling 67,086 shares dDecember 5, 2024 | marketbeat.comWhy Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 5, 2024 | msn.comParkman Healthcare Partners LLC Trims Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Parkman Healthcare Partners LLC trimmed its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 15.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 508,283 shares of the company'December 4, 2024 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 3, 2024 | prnewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eleven brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and ten have issued aDecember 3, 2024 | marketbeat.comEventide Asset Management LLC Acquires New Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Eventide Asset Management LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 786,990 shares of the company's stock, valued aNovember 29, 2024 | marketbeat.comSyndax Announces Participation at the Citi 2024 Global Healthcare ConferenceNovember 27, 2024 | prnewswire.comPropel Bio Management LLC Purchases 50,000 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Propel Bio Management LLC lifted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 60.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 133,259 shares of the company's stock after buying aNovember 26, 2024 | marketbeat.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Buys Shares of 787,785 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 787,785 shares of theNovember 24, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to "Sell" at StockNews.comStockNews.com lowered Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday.November 23, 2024 | marketbeat.comB. Riley Issues Optimistic Forecast for SNDX EarningsSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities research analysts at B. Riley upped their FY2024 EPS estimates for Syndax Pharmaceuticals in a research report issued on Monday, November 18th. B. Riley analyst K. Patel now expects that the company will post earnings per share oNovember 20, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for SNDX FY2024 Earnings?Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Syndax Pharmaceuticals in a research note issued on Monday, November 18th. HC Wainwright analyst E. White now anticipates that the company wNovember 20, 2024 | marketbeat.comSyndax Pharmaceuticals (SNDX) Gets a Buy from BarclaysNovember 19, 2024 | markets.businessinsider.comCitigroup Raises Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00Citigroup raised their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday.November 19, 2024 | marketbeat.comSyndax Pharmaceuticals’ Promising Outlook: Revumenib Approval and Market Potential Justify Buy RatingNovember 19, 2024 | markets.businessinsider.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stake Raised by First Turn Management LLCFirst Turn Management LLC boosted its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 85.4% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,187,165 shares of the company's stock after buying an additNovember 19, 2024 | marketbeat.comSyndax Pharmaceuticals Gains Buy Rating Boost from Revuforj’s Early Approval and Strategic Launch PlanNovember 18, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (SNDX) Gets a Buy from TD CowenNovember 18, 2024 | markets.businessinsider.comHC Wainwright Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock PriceHC Wainwright lifted their target price on shares of Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a "buy" rating in a research note on Monday.November 18, 2024 | marketbeat.comEarly FDA Approval of Revuforj Boosts Syndax Pharmaceuticals’ Prospects and Supports Overweight RatingNovember 18, 2024 | markets.businessinsider.comSyndax confirms FDA approval of Revuforj for acute leukemiaNovember 16, 2024 | markets.businessinsider.comFDA approves Syndax’s Revuforj for acute leukemiaNovember 16, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Raised to Hold at StockNews.comStockNews.com upgraded shares of Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday.November 16, 2024 | marketbeat.comUS FDA approves Syndax's blood cancer drugNovember 15, 2024 | reuters.comSyndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A TranslocationNovember 15, 2024 | prnewswire.comSimplify Asset Management Inc. Acquires 46,992 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Simplify Asset Management Inc. raised its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 62.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 122,185 shares of the company's stock after acquiring an additional 46,992 shareNovember 15, 2024 | marketbeat.comSyndax Pharmaceuticals: Promising Phase 2 Results Justify Buy Rating Amid Market UndervaluationNovember 14, 2024 | markets.businessinsider.comSyndax price target lowered to $18 from $23 at ScotiabankNovember 14, 2024 | markets.businessinsider.comSyndax's Revumenib Trial Reports Positive Data In Relapsed/Refractory MNPM1 AML PatientsNovember 12, 2024 | markets.businessinsider.comSyndax falls after mid-stage data for leukemia drugNovember 12, 2024 | msn.comSyndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of RevumenibNovember 12, 2024 | prnewswire.comAnalysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter ResultsNovember 9, 2024 | finance.yahoo.comScotiabank Remains a Hold on Syndax Pharmaceuticals (SNDX)November 7, 2024 | markets.businessinsider.comQ3 2024 Syndax Pharmaceuticals Inc Earnings CallNovember 7, 2024 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comSyndax Pharmaceuticals: Buy Rating Backed by Promising Revumenib Developments and Growth CatalystsNovember 7, 2024 | markets.businessinsider.com Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin SNDX Media Mentions By Week SNDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼0.760.65▲Average Medical News Sentiment SNDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼55▲SNDX Articles Average Week Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACLX News ADMA News APLS News RARE News BHVN News IMVT News RNA News SRRK News OGN News PTCT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
